27 results on '"van der Heijden, M."'
Search Results
2. Data analysis supports monitoring and surveillance of sheep health and welfare in the Netherlands
3. A0746 - Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)
4. Thermal disbudding in goat kids in the Netherlands: Current practice, complications and considerations
5. O-158 Perceptions and interventions of Dutch sheep farmers concerning coccidiosis
6. HYALURONIDASE VERSUS SURGICAL EXCISION OF GANGLIA: A PROSPECTIVE, RANDOMIZED CLINICAL TRIAL
7. Qualité de vie et symptômes chez les patients atteints d’un carcinome urothélial localement avancé ou métastatique précédemment traité de l’étude Ev-301 : une étude randomisée de phase 3 comparant enfortumab vedotin à la chimiothérapie
8. Introduction of a Nurse-Led Implantable Loop Recorder (ILR) Implantation Service
9. Preventive maintenance and the interval availability distribution of an unreliable production system
10. CtDNA as a predictor of outcome in patients treated with neoadjuvant atezolizumab in muscle invasive urothelial cancer
11. PD-0543: An externally validated prognostic CT radiomics model for head and neck cancer patients
12. 1243P - Tumour mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
13. 927P - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
14. 929P - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study
15. Classifieur génomique permettant d’identifier de tumeurs à profil génomique neuro-endocrine (« ne-like »)
16. OC-0487: EMT signatures as a prognostic marker for metastasis in HPV-negative HNSCC
17. 460 - Biological characterization of cisplatin-resistant bladder cancer: Implications for second-line treatments?
18. 91 - Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer
19. 94 - Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer
20. 8O_PR - TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma
21. 862P - Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective
22. OC-0463: In vitro prediction of DNA repair defects reveals association with poor clinical outcome in HNSCC
23. 901 - Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy
24. 888 - HIPEC with cytoreductive surgery can cure patients with limited peritoneal carcinomatosis from adenocarcinoma of the urachus
25. 782PD - IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
26. 783P - Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study
27. Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.